What is Nevoid Basal Cell Carcinoma Syndrome (NBCCS)? Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome, is a rare genetic disease that predisposes patients to develop multiple basal cell carcinomas (BCCs), mandibular cysts, and bone abnormalities. Causes and Risk Factors: Genetic mutation: NBCCS is linked to mutations in the PTCH1 gene, which...
AllCardiovascularChild DevelopmentCuba’s AchievementsCubaHeal NewsDermatologyEducationEndocrinologyGeriatricGynecologyInternational CollaborationMedical (General)NeurologyOncologyOphthalmologyOrthopedicPsychiatrySubstance Abuse RehabilitationTravel InsuranceUncategorized
Introduction: A Symbol of Cuban Innovation At the heart of Cuban medicine is an unwavering commitment: to provide innovative and accessible solutions to improve the quality of life of patients, both inside and outside its borders. HeberFERON, a revolutionary treatment for basal cell carcinoma (BCC), embodies this spirit of excellence. Developed at the prestigious Center...
Racotumomab: A Cuban Innovation for Non-Small Cell Lung Cancer Introduction: Racotumomab and Cuba’s Leadership in Oncology Cuba, recognized worldwide for its medical innovation and commitment to global health, has developed a promising solution for one of the most aggressive types of cancer: non-small cell lung cancer (NSCLC). Racotumomab, a therapeutic vaccine, is a clear example...
Cimavax-EGF for Non-small Cell Lung Cancer Vaccine Cimavax-EGF is the first worldwide registered therapeutic vaccine for non-small lung cancer developed in Cuba by the Center for Molecular Immunology in conjunction with the Center for Genetic Engineering and Biotechnology. In 2008 it was approved by the Cuban regulatory authority for the use in adults with advanced...
The recommended dose of CIMAher® is 200 mg given once a week for 6 weeks concomitant with radiotherapy and / or radio-chemotherapy. Subsequently, dose of 200 mg every 15 days (maintenance dose) until the general condition of the patient allows it.